The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Treatment of Older Patients with Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission. METHODS: We randomly assigned patients 60 years of age or older with mantle-cell lymphoma, stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabine, and cyclophosphamide (R-FC) every 28 days or to eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days. Patients who had a response underwent a second randomization to maintenance therapy with rituximab or interferon alfa, each given until progression. RESULTS: Of the 560 patients enrolled, 532 were included in the intention-to-treat analysis for response, and 485 in the primary analysis for response. The median age was 70 years. Although complete-remission rates were similar with R-FC and R-CHOP (40% and 34%, respectively; P=0.10), progressive disease was more frequent with R-FC (14%, vs. 5% with R-CHOP). Overall survival was significantly shorter with R-FC than with R-CHOP (4-year survival rate, 47% vs. 62%; P=0.005), and more patients in the R-FC group died during the first remission (10% vs. 4%). Hematologic toxic effects occurred more frequently in the R-FC group than in the R-CHOP group, but the frequency of grade 3 or 4 infections was balanced (17% and 14%, respectively). In 274 of the 316 patients who were randomly assigned to maintenance therapy, rituximab reduced the risk of progression or death by 45% (in remission after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% confidence interval, 0.36 to 0.87; P=0.01). Among patients who had a response to R-CHOP, maintenance therapy with rituximab significantly improved overall survival (4-year survival rate, 87%, vs. 63% with interferon alfa; P=0.005). CONCLUSIONS: R-CHOP induction followed by maintenance therapy with rituximab is effective for older patients with mantle-cell lymphoma. (Funded by the European Commission and others; ClinicalTrials.gov number, NCT00209209.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationA new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., et al. (2008) · Blood · doi:10.1182/blood-2007-06-095331 · Cited by 984
Self-citationCatovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M., Bezares, R., Pettitt, A., Hamblin, T., Milligan, D., Child, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61125-8 · Cited by 677
The Design and Analysis of Sequential Clinical Trials.
Harrington, D., & Whitehead, J. (1985) · Journal of the American Statistical Association · doi:10.2307/2288093 · Cited by 634
Loehrer, P. J. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79037-7 · Cited by 602
Forstpointner, R. (2004) · Blood · doi:10.1182/blood-2004-04-1323 · Cited by 580
Self-citationLenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Self-citationForstpointner, R., Unterhalt, M., Dreyling, M., Bock, H.-P., Repp, R., Wandt, H., Pott, C., Seymour, J. F., Metzner, B., Hanel, A., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016725 · Cited by 467
Self-citationMantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Pérez-Galán, P., Dreyling, M., & Wiestner, A. (2011) · Blood · doi:10.1182/blood-2010-04-189977 · Cited by 394
Self-citationHoward, O. M., Gribben, J. G., Neuberg, D. S., Grossbard, M. L., Poor, C., Janicek, M. J., & Shipp, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1288 · Cited by 372
Treatment of elderly patients with chronic lymphocytic leukemia
Eichhorst, B. F., Goede, V., & Hallek, M. J. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802688517 · Cited by 111
Self-citationCurrent treatment standards and emerging strategies in mantle cell lymphoma
Dreyling, M. H., Hiddemann, W., & for The European MCL Network (2009) · Hematology · doi:10.1182/asheducation-2009.1.542 · Cited by 108
Self-citationFu, K., & Hu, Q. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-5698-9_21 · Cited by 89
Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell Lymphoma
Cohen, B. J., Moskowitz, C., Straus, D., Noy, A., Hedrick, E. E., & Zelenetz, A. D. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109097721 · Cited by 75
Weigert, O., Pastore, A., Rieken, M., Lang, N., Hiddemann, W., & Dreyling, M. H. (2007) · Leukemia · doi:10.1038/sj.leu.2404511 · Cited by 72
Self-citation
Cited by
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Self-citationRituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Salles, G., Barrett, M., Foà, R., Maurer, J., O’Brien, S., Valente, N., Wenger, M., & Maloney, D. G. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0612-x · Cited by 620
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, C. S., Anderson, M. A., Pott, C., Agarwal, R., Handunnetti, S., Hicks, R. J., Burbury, K., Turner, G., Di Iulio, J., Bressel, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715519 · Cited by 433
Self-citationRituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
Le Gouill, S., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Dartigeas, C., Damaj, G., Gastinne, T., Ribrag, V., Feugier, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701769 · Cited by 416
Self-citation
Metadata
- Authors
- Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., Coiffier, B., Forstpointner, R., Tilly, H., Kanz, L., Feugier, P., Szymczyk, M., Hallek, M., Kremers, S., Lepeu, G., Sanhes, L., Zijlstra, J. M., Bouabdallah, R., Lugtenburg, P. J., Macro, M., Pfreundschuh, M., Procházka, V., Di Raimondo, F., Ribrag, V., Uppenkamp, M., André, M., Klapper, W., Hiddemann, W., Unterhalt, M., & Dreyling, M. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-08-09
- Volume
- 367
- Issue
- 6
- Pages
- 520-531
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2056952913
- Cited by
- 520
- References
- 17
- FWCI
- 38.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.